Compare REVB & SLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REVB | SLE |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.2M |
| IPO Year | N/A | 2019 |
| Metric | REVB | SLE |
|---|---|---|
| Price | $1.47 | $4.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 1.9M | 355.9K |
| Earning Date | 03-05-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,568,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.41 | $4.02 |
| 52 Week High | $54.48 | $278.35 |
| Indicator | REVB | SLE |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 57.80 |
| Support Level | $1.43 | $4.02 |
| Resistance Level | $1.63 | $4.78 |
| Average True Range (ATR) | 0.20 | 0.58 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 54.05 | 10.62 |
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.